Dew et al.,
I agree BMR has a while to go before most will forget the failures. I won't try and deny that. However, things are changing. There has been broader small to mid-cap coverage that has delivered results without pump and dump. Recently, DEPO and CHTP are prime examples of great companies I wrote about that have done well.
Articles have been well-balanced and are not entirely optimistic. ARYX went up 30% on an article I wrote that made it clear they may not even get a deal or survive before a deal is reached.
How is that pumping? It's not. I imagine most will still hold some of the failures against BMR, but things are changing and I think most will recognize that over time. It will take time to slowly build back respect and shake the P&D notion.
Additionally, I never claimed Lovenox was a biosimilar, if you read the article. What MNTA was approved for amounts to a biosimilar, in terms of their application and the rules for how the FDA approved them.
In regards to PPHM, I say nothing about PPHM being a serious player, except they have an interest in being in the game.
Market Data 
Markets 
AI
